Nuevos antiarrítmicos en lafibrilación auricular / New antiarrhythmic agents in atrial fibrillation
Arch. cardiol. Méx
; 77(supl.2): S2-59-S2-63, abr.-jun. 2007.
Artigo
em Espanhol
| LILACS
| ID: lil-568848
Biblioteca responsável:
BR1.1
ABSTRACT
The convenience to count with a safe and effective pharmacological wealth for atrial fibrillation treatment had conduced, in a way, to a deep depuration of the vast array of antiarrhythmic drugs, keeping only a very restricted number of compounds with a widely proved anti-atrial activity. On the other hand, it had lead to the discovery of the pathophysiological concepts that point to novel therapeutic targets. Within these objectives is that new antiarrhythmic drugs with preferential, even selective, activity on myocardial atrium ion channels had been developed. Among these new antiarrhythmics, dofetilide, and AVE0118, are taken into account. In addition, new possibilities are opened based on the knowledge of the cardioprotective-antiarrhythmic qualities of the opioidergic system.
Texto completo:
Disponível
Coleções:
Bases de dados internacionais
Base de dados:
LILACS
Assunto principal:
Fenetilaminas
/
Fibrilação Atrial
/
Sulfonamidas
/
Compostos de Bifenilo
/
Bloqueadores dos Canais de Potássio
/
Antiarrítmicos
Tipo de estudo:
Ensaio clínico controlado
Limite:
Humanos
Idioma:
Espanhol
Revista:
Arch. cardiol. Méx
Assunto da revista:
Cardiologia
Ano de publicação:
2007
Tipo de documento:
Artigo
País de afiliação:
México
Instituição/País de afiliação:
Instituto Nacional de Cardiología Ignacio Chávez/MX